

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in the Bermuda with limited liability)

(Stock Code: 02186)

**ANNOUNCEMENT
ESTABLISHMENT OF A SUBSIDIARY**

The board of directors (the “**Board**”) of Luye Pharma Group Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that Luye Pharma Venture Capital (“**Luye Venture Capital**”) was established in the Cayman Islands as a wholly-owned subsidiary of the Company, with the primary aim to make investments in the pharmaceutical industry.

In identifying suitable investment opportunities, Luye Venture Capital will generally consider from the perspectives of therapeutic area, product type and treatment methodology. In particular, Luye Venture Capital intends to invest in products which are in the Group’s key therapeutic areas (namely oncology, cardiovascular system, alimentary tract and metabolism and central nervous system) and in companies or products which are at development stage. Furthermore, Luye Venture Capital intends to make investments as a minority shareholder in projects related to the Group’s key therapeutic areas which have established business presence but require further investments to expand, including pre-IPO investments. Luye Venture Capital also intends to focus on cutting-edge projects that primarily involve innovative antibodies formulation, biological new formulation and targeted drug delivery formulation and personalised medicine etc.

The Group from time to time explores potential investment opportunities and holds discussions with target companies in the healthcare sector. As at the date of this announcement, the Group is not in any advanced discussions in respect of any potential investment. In the event that any investment materialises in the future, the Company will make further announcements as and where appropriate and will comply with all applicable requirements under the Rules Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 9 December 2015

As at the date of this announcement, the Executive Directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the Non-executive Directors are Mr. PAN Jian, Mr. LIU Dong and Ms. WANG Xin; and the Independent Non-executive Directors are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.